{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:58:32Z","timestamp":1777388312665,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.anai.2021.05.020","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T11:56:15Z","timestamp":1621770975000},"page":"165-175.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis"],"prefix":"10.1016","volume":"127","author":[{"given":"Susan","family":"Waserman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernie","family":"Avilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2)(suppl 2","key":"10.1016\/j.anai.2021.05.020_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13223-018-0280-7","article-title":"Allergic rhinitis","volume":"14","author":"Small","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2021.05.020_bib0002","unstructured":"American Academy of Allergy Asthma & Immunology. Allergy statistics.Available at: https:\/\/www.aaaai.org\/about-aaaai\/newsroom\/allergy-statistics. Accessed May 8."},{"key":"10.1016\/j.anai.2021.05.020_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13601-018-0212-0","article-title":"Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort","volume":"8","author":"Mu\u00f1oz-Cano","year":"2018","journal-title":"Clin Transl Allergy"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2165\/00044011-199611050-00004","article-title":"Work, classroom and activity impairment instruments","volume":"11","author":"Reilly","year":"1996","journal-title":"Clin Drug Investig"},{"issue":"suppl 4","key":"10.1016\/j.anai.2021.05.020_bib0005","first-page":"S235","article-title":"Effect of fexofenadine HC1 on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis","volume":"5","author":"Tanner","year":"1999","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0006","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0895-4356(00)00349-8","article-title":"The work impact of asthma and rhinitis: findings from a population-based survey","volume":"54","author":"Blanc","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0007","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0091-6749(94)90349-2","article-title":"Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials","volume":"93","author":"Juniper","year":"1994","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0008","first-page":"251","article-title":"Effects of allergy season on mood and cognitive function","volume":"71","author":"Marshall","year":"1993","journal-title":"Ann Allergy"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0009","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1081-1206(10)61013-7","article-title":"Sexual dysfunction in patients with allergic rhinoconjunctivitis","volume":"95","author":"Kirmaz","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2021.05.020_bib0010","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/cea.12121","article-title":"Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis","volume":"43","author":"Demoly","year":"2013","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5414\/ALX02120E","article-title":"ARIA guideline 2019: treatment of allergic rhinitis in the German health system","volume":"3","author":"Klimek","year":"2019","journal-title":"Allergol Select"},{"key":"10.1016\/j.anai.2021.05.020_bib0012","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13223-020-00436-y","article-title":"Towards definitive management of allergic rhinitis: best use of new and established therapies","volume":"16","author":"Hossenbaccus","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.05.020_bib0013","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision","volume":"140","author":"Bro\u017cek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2021.05.020_bib0014","unstructured":"Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Committee for Medicinal Products for Human Use, European Medicines Agency. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf. Accessed May 7, 2021"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaci.2015.12.1298","article-title":"Sublingual or subcutaneous immunotherapy for allergic rhinitis?","volume":"137","author":"Durham","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0016","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.anai.2019.12.025","article-title":"Clinical aspects of sublingual immunotherapy tablets and drops","volume":"124","author":"Tankersley","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2021.05.020_bib0017","unstructured":"American College of Allergy, Asthma, and Immunology. Sublingual immunotherapy. Available at: https:\/\/acaai.org\/allergies\/allergy-treatment\/allergy-immunotherapy\/sublingual-immunotherapy-slit. Accessed May 8, 2021."},{"key":"10.1016\/j.anai.2021.05.020_bib0018","series-title":"Grastek\u00ae product monograph","year":"2017"},{"key":"10.1016\/j.anai.2021.05.020_bib0019","unstructured":"ALK-Abell\u00f3 A\/S. Ragwitek\u00ae product monograph. Available at: https:\/\/pdf.hres.ca\/dpd_pm\/00039374.PDF. Accessed May 9, 2021."},{"key":"10.1016\/j.anai.2021.05.020_bib0020","series-title":"AcarizakTM product monograph including patient medication information","year":"2017"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaip.2014.09.018","article-title":"Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy","volume":"3","author":"Nelson","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4168\/aair.2018.10.1.1","article-title":"Efficacy and safety of subcutaneous allergen immunotherapy for allergic rhinitis","volume":"10","author":"Sohn","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0023","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjms.2019.02.004","article-title":"SCIT versus SLIT: which one do you recommend, doc?","volume":"357","author":"Chaaban","year":"2019","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.anai.2021.05.020_bib0024","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaip.2018.11.044","article-title":"Long-term efficacy and dose-finding trial of Japanese cedar pollen sublingual immunotherapy tablet","volume":"7","author":"Gotoh","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jaci.2018.12.1001","article-title":"The SQ tree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"143","author":"Biedermann","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0026","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/all.13606","article-title":"A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG 4 to allergens from all trees in the birch homologous group","volume":"74","author":"Couroux","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0027","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/pai.12984","article-title":"Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: a randomized trial in a pediatric population","volume":"30","author":"Okamoto","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0028","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaci.2016.09.043","article-title":"Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis","volume":"139","author":"Okubo","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2021.05.020_bib0029","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/all.13544","article-title":"Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children","volume":"73","author":"Masuyama","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jama.2016.21040","article-title":"Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial","volume":"317","author":"Scadding","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0031","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.alit.2019.07.007","article-title":"Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet","volume":"69","author":"Gotoh","year":"2020","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0032","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0033","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.anai.2018.02.003","article-title":"Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit","volume":"120","author":"Ellis","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.anai.2021.05.020_bib0034","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.jaip.2020.03.041","article-title":"Efficacy and safety of ragweed SLIT-tablet in children with allergic rhinoconjunctivitis in a randomized, placebo-controlled trial","volume":"8","author":"Nolte","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2222.2009.03381.x","article-title":"The minimal clinically important difference in allergic rhinitis","volume":"40","author":"Barnes","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2021.05.020_bib0036","unstructured":"American Thoracic Society. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Available at: https:\/\/www.thoracic.org\/members\/assemblies\/assemblies\/srn\/questionaires\/rqlq.php. Accessed February 3, 2021."},{"issue":"12","key":"10.1016\/j.anai.2021.05.020_bib0037","article-title":"Sublingual immunotherapy for allergic rhinitis","volume":"12","author":"Radulovic","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0038","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jaip.2019.01.015","article-title":"Validation of patient-reported outcomes for clinical trials in allergic rhinitis: a systematic review","volume":"7","author":"Calder\u00f3n","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2006.01312.x","article-title":"Recommendations for standardization of clinical trials with allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1398-9995.1998.tb04082.x","article-title":"Immunotherapy as an effective tool in allergy treatment","volume":"53","author":"Malling","year":"1998","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0041","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaci.2012.08.032","article-title":"Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE","volume":"130","author":"Cox","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0042","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11882-017-0687-0","article-title":"Allergen immunotherapy clinical trial outcomes and design: working toward harmonization of methods and principles","volume":"17","author":"Nelson","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0043","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/14740338.2015.1017468","article-title":"Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review","volume":"14","author":"Didier","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.anai.2021.05.020_bib0044","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00325481.2017.1302306","article-title":"A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice","volume":"129","author":"Bernstein","year":"2017","journal-title":"Postgrad Med"},{"issue":"1 suppl","key":"10.1016\/j.anai.2021.05.020_bib0045","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2021.05.020_bib0046","series-title":"Full Prescribing Information","article-title":"Grastek (Timothy grass pollen allergen extract tablet for sublingual use)","year":"2014"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0047","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anai.2014.04.018","article-title":"Safety and tolerability of a short ragweed sublingual immunotherapy tablet","volume":"113","author":"Nolte","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.05.020_bib0048","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2016.02.001","article-title":"Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008-2013)","volume":"116","author":"Epstein","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0049","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2011.02761.x","article-title":"Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile","volume":"67","author":"Calder\u00f3n","year":"2012","journal-title":"Allergy"},{"issue":"suppl 5","key":"10.1016\/j.anai.2021.05.020_bib0050","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1067\/mai.2001.118891","article-title":"Allergic rhinitis and its impact on asthma","volume":"108","author":"Bousquet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0051","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaci.2012.07.053","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs","volume":"130","author":"Bousquet","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2021.05.020_bib0052","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.46.12.895","article-title":"Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history","volume":"46","author":"Sibbald","year":"1991","journal-title":"Thorax"},{"issue":"4 Pt 1","key":"10.1016\/j.anai.2021.05.020_bib0053","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/ajrccm.162.4.9912033","article-title":"Quality of life in allergic rhinitis and asthma. A population-based study of young adults","volume":"162","author":"Leynaert","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2021.05.020_bib0054","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/all.12560","article-title":"Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma","volume":"70","author":"Maloney","year":"2015","journal-title":"Allergy"},{"issue":"16","key":"10.1016\/j.anai.2021.05.020_bib0056","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2021.05.020_bib0057","series-title":"Full Prescribing Information","article-title":"Ragwitek (short ragweed pollen allergen extract tablet for sublingual use)","year":"2014"},{"key":"10.1016\/j.anai.2021.05.020_bib0058","series-title":"Full Prescribing Information","article-title":"Oralair (sweet vernal, orchard, perennial rye, Timothy, and Kentucky blue grass mixed pollens allergen extract tablet for sublingual use)","year":"2014"},{"key":"10.1016\/j.anai.2021.05.020_bib0059","unstructured":"ALK-Abell\u00f3 A\/S. ODACTRA\u2122 house dust mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) allergen extract tablet for sublingual use. Available at: https:\/\/www.fda.gov\/media\/103380\/download. Accessed May 7, 2021"},{"issue":"4 Pt B","key":"10.1016\/j.anai.2021.05.020_bib0060","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbadis.2017.07.038","article-title":"On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease","volume":"1864","author":"Trampert","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"3","key":"10.1016\/j.anai.2021.05.020_bib0061","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2018.09.039","article-title":"Nasal allergen-neutralizing IgG 4 antibodies block IgE-mediated responses: novel biomarker of subcutaneous grass pollen immunotherapy","volume":"143","author":"Shamji","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0062","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2222.2007.02888.x","article-title":"BSACI guidelines for the management of allergic and non-allergic rhinitis","volume":"38","author":"Scadding","year":"2008","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0063","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2008.10.009","article-title":"Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis","volume":"123","author":"Wahn","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.05.020_bib0064","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5414\/ALX01534","article-title":"Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials","volume":"36","author":"Bufe","year":"2013","journal-title":"Allergologie"},{"issue":"2","key":"10.1016\/j.anai.2021.05.020_bib0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2021.05.020_bib0066","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.05.020_bib0067","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: World Allergy Organization position paper 2013 update","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621003811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621003811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:03Z","timestamp":1761053163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621003811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1081120621003811"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.05.020","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}